CIK 0001231457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $155,693
- in 6 filings
Net −$155,693. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-09-11 | Mirabelli Mary Director | Grant or award | +3,460 | 4,460 | ||
| 2023-09-11 | Mirabelli Mary Director | Grant or award · Stock Option (Right to Buy) | +4,397 | 4,397 | ||
| 2023-09-11 | Tyree James L Director | Grant or award | +3,460 | 12,460 | ||
| 2023-09-11 | Tyree James L Director | Grant or award · Stock Option (Right to Buy) | +4,397 | 4,397 | ||
| 2023-09-11 | Thomas John Director | Grant or award | +3,460 | 482,460 | ||
| 2023-09-11 | Thomas John Director | Grant or award · Stock Option (Right to Buy) | +4,397 | 4,397 | ||
| 2023-09-11 | Smither John W Director | Grant or award | +6,920 | 7,820 | ||
| 2023-09-11 | Smither John W Director | Grant or award · Stock Option (Right to Buy) | +8,447 | 8,447 | ||
| 2023-09-11 | Szalay Aladar 10% owner | Sale | −9,331 | $21.39 | $200K | 122,885 |
| 2023-09-11 | Szalay Aladar 10% owner | Sale | −23,020 | $22.55 | $519K | 99,865 |
| 2023-09-11 | Ryder Sean General Counsel | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2023-09-11 | Samuelson Doug Vice President, Finance | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2023-09-11 | Yu Yong VP, Clinical Trial Operations | Grant or award · Stock Option (right to buy) | +65,000 | 65,000 | ||
| 2023-09-11 | Cappello Joseph VP, Pharmaceutical Development | Grant or award · Stock Option (right to buy) | +65,000 | 65,000 | ||
| 2023-09-11 | Smalling Ralph Head of Regulatory | Grant or award | +10,000 | 12,065 | ||
| 2023-09-11 | Smalling Ralph Head of Regulatory | Grant or award · Stock Option (right to buy) | +54,000 | 54,000 | ||
| 2023-09-11 | Jewett Caroline Head of Quality | Grant or award | +20,000 | 21,135 | ||
| 2023-09-11 | Jewett Caroline Head of Quality | Grant or award · Stock Option (right to buy) | +88,000 | 88,000 | ||
| 2023-09-11 | Zak Lourie S. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2023-09-08 | Szalay Aladar 10% owner | Sale | −13,672 | $22.78 | $311K | 143,375 |
Page 14 of 16 · 315 trades